Werewolf Therapeutics (NASDAQ:HOWL) Stock Rating Upgraded by Zacks Research

Key Points

• Werewolf Therapeutics' stock rating has been upgraded by Zacks Research from a "hold" to a "strong-buy".
• The stock currently has a market capitalization of $73.17 million and a price target consensus of $8.00.
• Despite the upgrade, other analysts, including Bank of America and JMP Securities, have recently lowered their target prices for the stock.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) was upgraded by investment analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a research report issued on Thursday,Zacks.com reports.

Several other research analysts have also issued reports on HOWL. Bank of America cut their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research note on Monday, August 25th. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a report on Thursday, August 21st. Weiss Ratings reiterated a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reiterated a "buy" rating on shares of Werewolf Therapeutics in a report on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.00.

Werewolf Therapeutics Price Performance

HOWL stock opened at $1.60 on Thursday. Werewolf Therapeutics has a 1 year low of $0.60 and a 1 year high of $4.18. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.30 and a quick ratio of 5.30. The stock has a market cap of $73.17 million, a price-to-earnings ratio of -0.98 and a beta of 0.76. The company has a 50 day simple moving average of $1.56 and a 200 day simple moving average of $1.25.

Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.10. Research analysts anticipate that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently modified their holdings of the business. Vontobel Holding Ltd. purchased a new position in shares of Werewolf Therapeutics in the first quarter worth about $34,000. Charles Schwab Investment Management Inc. increased its stake in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock worth $93,000 after purchasing an additional 23,852 shares in the last quarter. MPM Asset Management LLC increased its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. Nuveen LLC bought a new position in shares of Werewolf Therapeutics in the first quarter valued at approximately $71,000. Finally, MPM Bioimpact LLC boosted its position in shares of Werewolf Therapeutics by 0.9% in the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock valued at $2,341,000 after acquiring an additional 20,799 shares during the period. Hedge funds and other institutional investors own 64.84% of the company's stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.